MedTrace Logo

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

NCT00894556 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-05-10

Study results available
· View outcomes & findings →

Summary

A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.

Conditions

  • Acute Migraine

Interventions

DRUG

rizatriptan

Single dose of 10 mg orally disintegrating tablet at onset of migraine attack

DRUG

Comparator: Placebo

Placebo to Rizatriptan

DRUG

Comparator: Sumatriptan

single dose of generic sumatriptan 100 mg at onset of migraine attack

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-10
Primary Completion
2010-01-12
Completion
2010-01-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00894556 on ClinicalTrials.gov